Exicure, Inc. (XCUR)
| Previous close | 0.5010 |
| Open | 0.4900 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4900 - 0.5099 |
| 52-week range | 0.3650 - 1.5000 |
| Volume | |
| Avg. volume | 220,983 |
| Market cap | 4.333M |
| Beta (5Y monthly) | 1.23 |
| PE ratio (TTM) | 0.28 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-K
CHICAGO, April 22, 2024--Exicure, Inc. ("Exicure" or the "Company") (Nasdaq: XCUR), announced today it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on April 17, 2024 notifying the Company that, as a result of the Company’s failure to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all pe
- Business Wire
Exicure, Inc. and Bluejay Therapeutics Inc. Enter into a Patent License Agreement to Develop Cavrotolimod for the Treatment of Hepatitis
CHICAGO, February 05, 2024--Exicure, Inc., (NASDAQ:XCUR) a company that historically developed nucleic acid therapies, and Bluejay Therapeutics, Inc., a private clinical stage biopharmaceutical company focused on viral and liver diseases, announced today that Bluejay Therapeutics, Inc. ("Bluejay") and Exicure, Inc. ("Exicure") entered into a patent license agreement to develop cavrotolimod for potential treatment for hepatitis.
- Business Wire
Exicure, Inc. Announces Appointment of New CEO and CFO and Changes to Board of Directors
CHICAGO, August 23, 2023--Exicure, Inc. announces appointment of new CEO and CFO and changes to Board of Directors.
